Research And Development Tenders

Completion of a Non-Excl. Discount Agreement According to § 130A Paragraph 8 Sgb V for Isosorbide Dinitrate, Atc Code: C01da08 for the Period from 06/01/2023 to 05/31/2025

Conclusion of Non-Exclusive Discount Agreements According to § 130A Para. 8 Sgb V for the in Ii.2.4. Mentioned Active Ingredients with the Possibility of Conclusion Within the Framework of the So-Called Open-House Procedure.

Medicines Containing the Active Ingredient Mepolizumab (Atc: R03dx09)

Completion of a Non-Excl. Discount Agreement According to § 130A Paragraph 8 Sgb V for Vinorelbine, Atc Code: L01ca04 for the Period from 06/01/2023 to 05/31/2025

Drugs with the Active Ingredient Ibuprofen (Atc: M01ae01 - in Sustained-Release Dosage Form with a Potency of 800 Mg)

Conclusion of Non-Exclusive Discount Agreements According to § 130A Para. 8 Sgb V for the in Ii.2.4. Mentioned Active Ingredients with the Possibility of Conclusion Within the Framework of the So-Called Open-House Procedure.

Dynamic Procurement System for Food and Beverage Procurement

Open House Original Discount Contracts 2023-14 - Tafamidis (61Mg Strength and 20Mg Strength)

Completion of a Non-Excl. Discount Agreement According to § 130A Paragraph 8 Sgb V for Benralizumab, Atc Code: R03dx10 for the Period from 06/01/2023 to 05/31/2025

Completion of a Non-Excl. Discount Agreement According to § 130A Paragraph 8 Sgb V for Filgrastin, Atc Code: L03aa02 for the Period from 06/01/2023 to 05/31/2025